D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)

Analysts at D. Boral Capital initiated coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a note issued to investors on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $9.00 price target on the stock.

Several other research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a report on Tuesday, November 26th. Ascendiant Capital Markets cut their price target on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th.

Plus Therapeutics Stock Performance

NASDAQ PSTV opened at $0.56 on Monday. Plus Therapeutics has a one year low of $0.24 and a one year high of $2.67. The company’s 50 day moving average price is $1.10 and its 200 day moving average price is $1.24. The firm has a market capitalization of $3.29 million, a price-to-earnings ratio of -0.22 and a beta of 0.73.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.